THE INVENTION Sample Clauses

THE INVENTION. An ultra-compact holographic sensor allowing real-time monitoring of the size, concentration and shape of particles, typically from 4-40μm or larger, in confined industrial areas in order to ensure continuous monitoring and prevent fires and explosions. Due to the configuration, all the electronics of the sensor can be securely confined to avoid any risk of electrical discharge. The patent claims a compact holographic sensor which consists in using a network of endoscopic fiber array coupled to the camera sensor. The object hologram that is incident on the free entry window of the fiber array, away from the camera, is directly propagated and imaged onto the camera's sensitive sensor. We can thus achieve holographic recording of experimental volumes inaccessible by other techniques.
Sample 1
AutoNDA by SimpleDocs
THE INVENTION. Inventor has invented, conceived, developed and reduced to practice a certain invention relating to the use of polymers as a soil additive. The polymers improve moisture retention of the soil and reduce fertilizer consumption of agricultural crops. This invention is referred to in this Agreement as the "Invention." The Invention also includes any and all improvements, enhancements and variations of the Invention heretofore or hereafter made or acquired by Inventor. The Invention has been patented by Inventor. The patents (referred to herein as the "Licensed Patents") covering the Invention are United States Patent Nos. 5,649,495 and 5,868,087.
Sample 1
THE INVENTION. The Parties agree that under this Agreement, the Assignor shall assign, convey, and transfer all their interest in the following to the Assignee:
Sample 1
THE INVENTION. The Parties agree that under this Agreement, the Assignor shall assign, convey, and transfer all their interest in the following to the Assignee: [DESCRIBE WHAT IS BEING ASSIGNED] Hereinafter known as the “Assignment.”
Sample 1
THE INVENTION. The combined use of two drugs to activate latent HIV could cause a synergistic reactivation of HIV-1 production. Indeed, a proof-of-concept has been demonstrated by inventors for the coadministration of two different types of therapeutically promising HIV-1 inducers [DNA methylation inhibitors in combination with histone deacethylase inhibitors (HDACis) or histone methyltransferase inhibitors (HMTis) in combination with HDACi or NF-kappaB inducers] together with efficient cART as a thera- peutic perspective to decrease the pool of latent HIV-1 reservoirs.
Sample 1
THE INVENTION. The invention consists in an implant composed of magnets linked together by a wire. Through na- tural ducts—such as the esophagus—and using endoscopic tools, the magnets are positioned over the tissue to be cut (such as the wall between the esophagus and a diverticulum). The magnets strongly compress the tissue thus trapped, cutting it off from its blood supply. This results in tis- sue necrosis between the magnets and scarification at the edges, preventing an open wound. At the same time, the wire linking the magnets exerts a compression force on the remaining tissue, due to gravity affecting the magnets or to any other system creating a tension, resulting in a slow and atraumatic cutting of the tissue. Performing an anastomosis with a double MAGUS prototype.
Sample 1
THE INVENTION. The objective of the present invention is to provide a device for plasma generation and transport with a high efficiency over a long distance and allowing for a controlled and uniform treatment of large surfaces. The plasma is carried at a long distance from its generation to finally exit at the end of the system to treat efficiently a target area while sparing adjacent areas of tissue with improved control during treatment. This device is built to perform an ablation of mucosa (i.e. duodenal mucosa) in a minimally invasive way (endoscopically). • Homogeneity of treatment. • No inflammation due to cell-induced death. • Fast treatment (<1hour). • Versatile device (i.e. can treat any mucosa of the gastro-intestinal tract). • Ablation of the duodenal lining • Regeneration of mucosa • Insulin resistance disease (Type 2 Diabetes - TD2) and NonAlcoholic SteatoHepatitis (XXXX) • Barret’s Oesophagus
Sample 1
AutoNDA by SimpleDocs
THE INVENTION. The present invention is directed to the use of the heptapeptide of angiotensin (Ang-1- 7) as biomarker for the prognosis and early decision-making of therapeutic treatment in COVID-19 patients. According to blood level of Ang-1-7, stratification of patients’ subpopulation at higher or lower risk of COVID-19 pulmonary fibrosis/sequelae is achieved. The combination of Ang-1-7 with additional markers provides means to rapidly provide the most appropriate treatment to the patients according to their risk profile ranging from mild treatment, Ang-1-7 agonists, antifibrotics or monoclonal therapeutic antibodies and/or oxygen supplementation at an early stage of the disease progression. This comprehensive patient stratification method is also of interest in the design of clinical trials so as to assess treatment efficacy according to subgroups of patients. • Early diagnosis of disease severity • Global comprehensive prediction test discriminating at-risk patients subpopulation • Therapeutic treatment decision tree based on composite index • Potential to limit post-acute sequelae for patients The technology is conducive to development of immunoassays including ELISA and CLEIA kits directly useful in clinical settings and could therefore efficiently contribute to limit clinical complications for COVID-19 patients receiving the most suitable treatment rapidly upon admission at the hospital. • COVID-19 patient stratification upon hospital admission for therapeutic treatment decision-making • Companion diagnostic for innovative treatment (therapeutic antibodies) under development • Possible implementation on automated CLEIA platforms
Sample 1

Related to THE INVENTION

  • Invention The term “

  • Prior Inventions Inventions, if any, patented or unpatented, which I made prior to the commencement of my employment with the Company are excluded from the scope of this Agreement. To preclude any possible uncertainty, I have set forth on Exhibit A (Previous Inventions) attached hereto a complete list of all Inventions that I have, alone or jointly with others, conceived, developed or reduced to practice or caused to be conceived, developed or reduced to practice prior to the commencement of my employment with the Company, that I consider to be my property or the property of third parties and that I wish to have excluded from the scope of this Agreement (collectively referred to as “Prior Inventions”). If disclosure of any such Prior Invention would cause me to violate any prior confidentiality agreement, I understand that I am not to list such Prior Inventions in Exhibit A but am only to disclose a cursory name for each such invention, a listing of the party(ies) to whom it belongs and the fact that full disclosure as to such inventions has not been made for that reason. A space is provided on Exhibit A for such purpose. If no such disclosure is attached, I represent that there are no Prior Inventions. If, in the course of my employment with the Company, I incorporate a Prior Invention into a Company product, process or machine, the Company is hereby granted and shall have a nonexclusive, royalty-free, irrevocable, perpetual, worldwide license (with rights to sublicense through multiple tiers of sublicensees) to make, have made, modify, use and sell such Prior Invention. Notwithstanding the foregoing, I agree that I will not incorporate, or permit to be incorporated, Prior Inventions in any Company Inventions without the Company’s prior written consent.

  • Inventions (i) The Employee acknowledges and agrees that all ideas, methods, inventions, discoveries, improvements, work products or developments (“Inventions”), whether patentable or unpatentable, (A) that relate to the Employee’s work with the Company, made or conceived by the Employee, solely or jointly with others, during the Employment Term, or (B) suggested by any work that the Employee performs in connection with the Company, either while performing the Employee’s duties to the Company or on the Employee’s own time, but only insofar as the Inventions are related to the Employee’s work as an employee or other service provider to the Company, shall belong exclusively to the Company (or its designee), whether or not patent applications are filed thereon. The Employee will keep full and complete written records (the “Records”), in the manner prescribed by the Company, of all Inventions, and will promptly disclose all Inventions completely and in writing to the Company. The Records shall be the sole and exclusive property of the Company, and the Employee will surrender them upon the termination of the Employment Term, or upon the Company’s request. The Employee will assign to the Company the Inventions and all patents that may issue thereon in any and all countries, whether during or subsequent to the Employment Term, together with the right to file, in the Employee’s name or in the name of the Company (or its designee), applications for patents and equivalent rights (the “Applications”). The Employee will, at any time during and subsequent to the Employment Term, make such applications, sign such papers, take all rightful oaths, and perform all acts as may be requested from time to time by the Company with respect to the Inventions. The Employee will also execute assignments to the Company (or its designee) of the Applications, and give the Company and its attorneys all reasonable assistance (including the giving of testimony) to obtain the Inventions for its benefit, all without additional compensation to the Employee from the Company, but entirely at the Company’s expense. (ii) In addition, the Inventions will be deemed Work for Hire, as such term is defined under the copyright laws of the United States, on behalf of the Company and the Employee agrees that the Company will be the sole owner of the Inventions, and all underlying rights therein, in all media now known or hereinafter devised, throughout the universe and in perpetuity without any further obligations to the Employee. If the Inventions, or any portion thereof, are deemed not to be Work for Hire, the Employee hereby irrevocably conveys, transfers and assigns to the Company, all rights, in all media now known or hereinafter devised, throughout the universe and in perpetuity, in and to the Inventions, including, without limitation, all of the Employee’s right, title and interest in the copyrights (and all renewals, revivals and extensions thereof) to the Inventions, including, without limitation, all rights of any kind or any nature now or hereafter recognized, including without limitation, the unrestricted right to make modifications, adaptations and revisions to the Inventions, to exploit and allow others to exploit the Inventions and all rights to xxx at law or in equity for any infringement, or other unauthorized use or conduct in derogation of the Inventions, known or unknown, prior to the date hereof, including, without limitation, the right to receive all proceeds and damages therefrom. In addition, the Employee hereby waives any so-called “moral rights” with respect to the Inventions. The Employee hereby waives any and all currently existing and future monetary rights in and to the Inventions and all patents that may issue thereon, including, without limitation, any rights that would otherwise accrue to the Employee’s benefit by virtue of the Employee being an employee of or other service provider to the Company.

  • INTELLECTUAL PROPERTY RIGHTS - INVENTION AND PATENT RIGHTS A. General 1. NASA has determined that 51 U.S.C. § 20135(b) does not apply to this Agreement. Therefore, title to inventions made (conceived or first actually reduced to practice) under this Agreement remain with the respective inventing party(ies). No invention or patent rights are exchanged or granted under this Agreement, except as provided herein.

  • NASA Inventions NASA will use reasonable efforts to report inventions made under this Agreement by its employees. Upon request, NASA will use reasonable efforts to grant Partner, under 37 C.F.R. Part 404, a negotiated license to any NASA invention made under this Agreement. This license is subject to paragraph E.1. of this Article.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!